Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Story Feb. 11 - Third Harmonic Bio: The biotech announced it will lay off half of its workforce as it prepares to take its chronic spontaneous urticaria candidate into phase 2. Story Feb. 10 - Q32 ...

The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...

New research by the FINEXT-BD data has found that individuals suffering from bipolar disorder are at an increased risk of ...